Tag: tirnovetmab
-
Elanco Announces USDA Approval of Befrena (tirnovetmab): A New Anti-IL31 Therapy for Canine Dermatitis
Elanco Secures USDA Approval for Befrena, a Breakthrough Anti-IL31 Therapy Elanco Animal Health has obtained United States Department of Agriculture (USDA) approval for Befrena, a novel monoclonal antibody injection designed to target interleukin-31 (IL-31) in dogs. Known chemically as tirnovetmab, Befrena represents a new class of dermatology treatment intended to ease the burden of canine…
-
Befrena: Elanco’s Anti-IL31 Therapy for Canine Dermatitis
Overview of Befrena’s U.S. Regulatory Milestone Elanco announced that Befrena™ (tirnovetmab), a novel anti-IL31 monoclonal antibody injection, has received approval from the U.S. Department of Agriculture (USDA). This marks a significant regulatory achievement for Elanco in the estimated $1.3 billion U.S. canine dermatology market, and it introduces a new targeted option for dogs suffering from…
-
Elanco Wins USDA Nod for Befrena (tirnovetmab): A New Targeted Therapy for Canine Atopic Dermatitis
Overview: A New Anti-IL31 Monoclonal Antibody for Dogs Elanco announced USDA approval for Befrena™ (tirnovetmab), a novel anti-IL31 monoclonal antibody injection designed to help dogs manage allergic and atopic dermatitis. As the canine dermatology market grows—estimated at about $1.3 billion in the United States—Befrena represents the company’s second dermatology product approval in under 18 months,…